Iruxol Mono

Collagenase clostridium histolyticum, the active ingredient in Iruxol, is a proteolytic enzyme presented as a topical preparation for cutaneous use. It enzymatically debrides chronic wounds, pressure ulcers and burn eschar by breaking down collagen and other extracellular matrix proteins, facilitating removal of necrotic tissue. The enzymatic activity targets the structural proteins that maintain the integrity of dead tissue, allowing clinicians to clean the wound bed without surgical excision.

GNH USA supplies Iruxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iruxol Mono, a proteolytic enzyme used for topical debridement, is indicated for the following wound‑related conditions: - Chronic wounds: facilitates removal of necrotic tissue and promotes a clean wound bed for healing. - Pressure ulcers: enzymatically debrides eschar, improving ulcer management and reducing infection risk. - Burn eschar: breaks down dead burn tissue, supporting subsequent grafting or natural healing.

Topical application of Iruxol Mono may be associated with local skin reactions and, rarely, systemic adverse events.

Common Side Effects: - Local pain: mild to moderate discomfort at the application site. - Redness: erythema surrounding the treated area. - Swelling: transient edema of the wound margins. - Itching or burning sensation: transient pruritus or burning feeling. - Bleeding: minor oozing from the debrided tissue. - Drainage: serous fluid discharge from the wound.

Serious or Rare Side Effects: - Allergic reaction: signs of hypersensitivity such as urticaria, angioedema, or anaphylaxis. - Severe skin necrosis: excessive tissue breakdown beyond the intended area. - Infection: secondary bacterial infection of the debrided wound.

When using Iruxol Mono, clinicians should observe the following precautions to ensure safety and effectiveness. - Wound assessment: confirm that the tissue is necrotic and suitable for enzymatic debridement. - Healthy tissue avoidance: do not apply to intact skin or viable tissue. - Allergy screening: check for known hypersensitivity to collagenase or related enzymes. - Infection control: avoid use on infected wounds unless combined with appropriate antimicrobial therapy. - Concomitant therapies: be cautious when using other topical debriding agents or proteolytic preparations. - Store at ambient temperature: keep the product in its original container, protect from moisture and light.

Iruxol Mono may interact with other topical agents; the following interactions should be considered.

Major Interactions (Avoid): - Concurrent use with other proteolytic enzymes: may cause excessive tissue breakdown. - Combination with strong topical irritants (e.g., phenol): increases risk of skin damage.

Moderate Interactions (Monitor Closely): - Use with silver‑containing dressings: may reduce enzymatic activity. - Application together with topical corticosteroids: may delay wound healing. - Co‑administration with systemic anticoagulants: may enhance local bleeding.